Search the Newsreel

MNKD: Phase I-B data show nintedanib DPI is safe and well-tolerated in IPF, enabling phase II advancement

MannKind Corporation (MNKD) announced positive Phase I-B results for its nintedanib Dry Powder Inhaler (DPI) in Idiopathic Pulmonary Fibrosis (IPF) patients. The study demonstrated strong safety and tolerability, with no serious adverse events and effective lung delivery, paving the way for a global Phase …

MannKind’s Inhaled Nintedanib Passes Safety Test in IPF Patients, Paving Way for Global Phase 2 Trial

MannKind's inhaled nintedanib therapy for Idiopathic Pulmonary Fibrosis (IPF) successfully cleared a Phase 1b safety study, demonstrating no serious adverse events or significant gastrointestinal side effects in 27 patients. This positive outcome, building on earlier healthy volunteer data, paves the way for a global …

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MannKind Corporation (MNKD) will release its second quarter financial results on August 5, 2026, after the market closes. The company will also host a conference call and webcast at 5:00 PM ET on the same day to discuss the results and provide a business …

MNKD: Nintedanib DPI demonstrated strong safety and tolerability in IPF, supporting Phase 2 advancement

MannKind Corporation (MNKD) has announced Phase 1b results for nintedanib DPI, showing it to be safe and well-tolerated in Idiopathic Pulmonary Fibrosis (IPF) patients. The study reported no serious adverse events or discontinuations, with only mild, transient coughs. These positive results support the advancement …

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in patients with IPFGlobal Phase 2 INFLO-2 trial actively enrolling patientsConference call and webcast scheduled for July …

MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MannKind Corp (MNKD), detailing its price momentum score within the Biotechnology & Medical Research industry. It outlines the stock's current trading range between support and resistance levels, and analyzes various technical indicators like MACD, RSI, and Moving …

MannKind (MNKD) to Release Earnings on Wednesday

MannKind will review second-quarter results in Aug. 5 webcast

MannKind Corporation (Nasdaq: MNKD) announced it will report its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. The management team will host a conference call and live webcast at 4:30 p.m. Eastern Time to review the results and provide a …

H.C. Wainwright reiterates MannKind stock rating on FDA approval

H.C. Wainwright maintained a Buy rating and a $10.00 price target for MannKind (NASDAQ:MNKD) after the FDA approved FUROSCIX ReadyFlow, citing a potential upside of 142%. The firm expects ReadyFlow, an autoinjector for furosemide, to significantly boost revenue and margins starting in 2027, especially …

MannKind Corp (MNKD) Cash Flow

This article provides a comprehensive overview of MannKind Corp's (MNKD) cash flow, including operating, investing, and financing activities across various fiscal quarters. It details changes in key cash flow metrics such as net income, capital expenditures, and free cash flow over time, presenting raw …

MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of MannKind Corp's (MNKD) revenue for fiscal year 2025, categorized by business segments and geographic region. Product sales constitute the largest portion at 62.05%, followed by royalties and services. The company's entire reported revenue for this period originates …

MannKind Corp (MNKD) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of MannKind Corp (MNKD) focusing on its dividend history and stock splits. It indicates that the company has distributed $0.00 in dividends over the past five years and contains no specific dividend or stock split data. The page also …

MannKind Corporation Revenue Breakdown – DUS:NNFN

This article details MannKind Corporation's revenue breakdown, highlighting that the company generated 297.12 million EUR last year, primarily from its Innovative Therapeutic Products and Devices segment. The United States was the largest geographical contributor to this revenue.

MannKind (MNKD) Following Furoscix Approval, Buying Opportunity Or Already Priced In?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. MannKind (MNKD) is in focus after the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart …

How Investors May Respond To MannKind (MNKD) Winning FDA Approval For At‑Home Furoscix Autoinjector

MannKind Corporation has now received U.S. FDA approval for Furoscix ReadyFlow, an at-home autoinjector delivering an IV‑equivalent 80 mg/mL furosemide dose in under 10 seconds to treat edema in adults with heart failure or chronic kidney disease. This second Furoscix presentation could materially extend …

The Bull Case For MannKind (MNKD) Could Change Following FDA Approval Of At-Home Furoscix ReadyFlow Autoinjector – Learn Why

MannKind Corporation recently received FDA approval for Furoscix ReadyFlow, an at-home autoinjector for treating edema in heart failure and chronic kidney disease patients. This approval introduces a new at-home care option and could influence MannKind's investment narrative, although the company still faces challenges with …

MannKind Corporation (MNKD) stock price, news, quote and history

This article provides a comprehensive overview of MannKind Corporation (MNKD) stock, including its current price, historical performance, key financial metrics, and analyst insights. It details the company's biopharmaceutical focus on chronic disease care, its product offerings like Afrezza and Tyvaso DPI, and its pipeline. …

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

The FDA has approved MannKind's Furoscix ReadyFlow, an autoinjector delivering furosemide for edema in adults with heart failure or chronic kidney disease, allowing for at-home treatment. This approval triggered a $45 million contingent value rights payment, which MannKind plans to fund through a $50 …

MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says

MannKind (MNKD) is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …

MannKind shares surge after FDA approves Furoscix ReadyFlow and company secures $50 million financing

MannKind Corporation's shares rose by approximately 6% following FDA approval for its Furoscix ReadyFlow autoinjector, a new and faster treatment for oedema in heart failure and chronic kidney disease patients. The company also announced a $50 million private placement, with proceeds intended for general …

MannKind stock jumps 6% on FDA approval, $50M financing

MannKind Corporation (NASDAQ:MNKD) shares increased by 6% following FDA approval for Furoscix ReadyFlow, an autoinjector designed for at-home treatment of edema in adults with heart failure or chronic kidney disease. The company also announced a $50 million private placement, with proceeds intended for general …

MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector

MannKind (Nasdaq:MNKD) has announced it secured $50 million in a private placement and received FDA approval for its Furoscix ReadyFlow auto-injector. Frazier Life Sciences led the financing, which is expected to close today, July 24. The proceeds will be used for general corporate purposes, …

MannKind Announces $50 Million Private Placement

MannKind Corporation announced a private placement totaling $50 million, led by Frazier Life Sciences. The funding will be used for general corporate purposes, including a $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow™. The company is selling …

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

MannKind Furoscix ReadyFlow [prototype]The U.S. FDA has approved Furoscix ReadyFlow (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease. Transformative delivery option that may support earlier management of worsening fluid overload with a self-administered option …

At-home autoinjector delivers IV-equivalent therapy in under 10 seconds

MannKind Corporation (Nasdaq: MNKD) has received FDA approval for Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for edema in adults with heart failure or chronic kidney disease. This new device provides an 80 mg/mL furosemide dose in less than 10 seconds, significantly reducing …

Form 4 MannKind Corp For: 21 July By Investing.com

This article is a brief financial bulletin from Investing.com, reporting a Form 4 filing for MannKind Corp on July 21. It mentions that shares of MNKD were down 5.19% and concludes with additional market data and related news.

MannKind Executive Sells 123,000 Shares Amid Performance Concerns

MannKind's EVP David Thomson sold 123,000 shares, worth approximately $500,000, between July 15 and 17, 2026, with a significant portion withheld for tax liabilities. The sale follows the vesting of performance shares at 83% of target, reflecting MannKind's underperformance relative to its peers. The …

MannKind EVP David Thomson sells $97,641 in MNKD shares on July 17

MannKind Corp's EVP, David Thomson, sold 24,109 shares totaling $97,641 on July 17, 2026, after acquiring 93,790 shares from a performance-based RSU award. He also disposed of shares worth $402,562 to cover tax liabilities. Despite past unprofitability, analysts predict MannKind will be profitable this …

Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk

A recent non-discretionary stock sale by MannKind's chief people & workplace officer, Stuart A. Tross, to cover tax liabilities, involved 65,808 shares and is less significant than the potential loss of a 9% royalty from United Therapeutics' Tyvaso DPI. The shares vested based on …

MannKind CEO Sells Shares to Cover Tax Liabilities

MannKind CEO Michael Castagna sold 363,200 shares amounting to $1.5 million on July 15, 2026, to cover tax liabilities from restricted stock unit vesting, demonstrating a common executive financial practice rather than a shift in investment outlook. Following the sale, Castagna retains 2,433,779 shares, …

What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk

Director Steven B. Binder disclosed a disposition of 76,880 shares of MannKind Corporation (NASDAQ:MNKD) at $4.07 per share in transactions completed on July 15, 2026, and July 17, 2026, according to a recent SEC Form 4 filing. Transaction summary Metric Value Shares sold 76,880 …

Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?

Key Points The disposition involved ~363,000 shares valued at ~$1.5 million as of the July 15, 2026 transaction date. The activity represents 13% of the executive’s direct equity holdings in the company. The transaction was a non-discretionary execution conducted to satisfy tax withholding obligations …

Mankind Pharma to host Q1FY27 earnings call on July 30

MannKind EVP David Thomson sells $97,641 in company stock By Investing.com

MannKind EVP David Thomson sold $97,641 worth of company stock on July 17, 2026, as part of a pre-arranged trading plan. This sale followed his acquisition of 93,790 shares through the vesting of a Performance Restricted Stock Unit award tied to specific company performance …

MannKind Corp (MNKD) EVP receives 70,550 shares from performance RSUs

Sanjay R. Singh, EVP of Technical Operations at MannKind Corp (MNKD), received 70,550 common shares on July 15, 2026, from the vesting of a performance-based restricted stock unit award granted in May 2023. The performance objectives were met at 83% of the target, leading …

MannKind (MNKD) CEO vests 350,260 shares, withholds stock for taxes

MannKind CEO Michael Castagna received 350,260 shares of common stock on July 15, 2026, from a performance-based restricted stock unit award that vested at 83% of its target. To cover tax obligations, 363,200 shares were withheld at $4.09 per share. Following these transactions, Castagna …